Facilitation of Beta Selection and Modification of Positive Selection in the Thymus of PD-1-deficient Mice
Overview
General Medicine
Authors
Affiliations
PD-1 is an immunoglobulin superfamily member bearing an immunoreceptor tyrosine-based inhibitory motif, and disruption of the PD-1 gene results in the development of lupus-like autoimmune diseases. In this study, we examined effects of the PD-1 deficiency on the thymocyte differentiation at the clonal level using T cell receptor (TCR)-beta (Vbeta8) and TCR-alpha/beta (H-Y and 2C) transgenic mice. In these TCR transgenic lines, PD-1 expression in the thymus was variably augmented, but as in the normal mice, confined largely to the CD4(-)CD8(-) thymocytes. The transgenic mice crossed with PD-1(-/)- mice in the neutral genetic backgrounds exhibited selective increase in the CD4(+)CD8(+) (DP) population with little effect on other thymocytes subsets. Similarly, the absence of PD-1 facilitated expansion of DP thymocytes in recombination activating gene (RAG)-2(-/)- mice by anti-CD3epsilon antibody injection. On the other hand, H-Y or 2C transgenic PD-1(-/)- mice with the positively selecting background showed significantly reduced efficiency for the generation of CD8(+) single positive cells bearing the transgenic TCR-alpha/beta in spite of the increased DP population. These results collectively indicate that PD-1 negatively regulates the beta selection and modulates the positive selection, and suggest that PD-1 deficiency may lead to the significant alteration of mature T cell repertoire.
Mao Z, Hirdler J, Gicobi J, Maynes M, Hsu M, Dellacecca E bioRxiv. 2025; .
PMID: 39868106 PMC: 11761021. DOI: 10.1101/2025.01.18.631253.
Sagrero-Fabela N, Chavez-Mireles R, Salazar-Camarena D, Palafox-Sanchez C Int J Mol Sci. 2024; 25(14).
PMID: 39062968 PMC: 11277507. DOI: 10.3390/ijms25147726.
Stergiou I, Palamaris K, Levidou G, Tzimou M, Papadakos S, Mandrakis G Biomedicines. 2024; 12(4).
PMID: 38672128 PMC: 11048374. DOI: 10.3390/biomedicines12040772.
PD-1 Limits IL-2 Production and Thymic Regulatory T Cell Development.
Caruso B, Weeder B, Thompson R, Moran A Immunohorizons. 2024; 8(3):281-294.
PMID: 38551395 PMC: 10985057. DOI: 10.4049/immunohorizons.2300079.
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
Raskova Kafkova L, Mierzwicka J, Chakraborty P, Jakubec P, Fischer O, Skarda J Front Immunol. 2024; 15:1342086.
PMID: 38384472 PMC: 10879685. DOI: 10.3389/fimmu.2024.1342086.